Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Insider and Institutional Ownership
77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 7.1% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Pulse Biosciences and Envoy Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Envoy Medical | 1 | 1 | 1 | 0 | 2.00 |
Earnings & Valuation
This table compares Pulse Biosciences and Envoy Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 5,006.45 | -$72.78 million | ($1.10) | -23.02 |
| Envoy Medical | $240,000.00 | 205.01 | -$23.76 million | ($1.01) | -0.63 |
Envoy Medical has lower revenue, but higher earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Pulse Biosciences and Envoy Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | N/A | -86.67% | -73.61% |
| Envoy Medical | -9,875.64% | N/A | -177.92% |
Risk and Volatility
Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Summary
Pulse Biosciences beats Envoy Medical on 8 of the 14 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About Envoy Medical
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
